Apr 9 |
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
|
Apr 3 |
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
|
Mar 25 |
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
|
Mar 23 |
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company
|
Mar 4 |
Astria TherapeuticS GAAP EPS of -$2.42 misses by $0.19
|
Mar 4 |
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
|
Feb 20 |
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
|
Feb 6 |
Astria Therapeutics 10% owner Perceptive Advisors discloses purchase of 2.48M shares
|
Feb 6 |
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
Feb 4 |
Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout
|